Literature DB >> 1552096

Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.

B J Schrader1, S Inbar, L Kaufmann, R E Vestal, S Rich.   

Abstract

The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension. All patients were given adenosine, 50 micrograms/kg per min, increased by 50 micrograms/kg per min at 2 min intervals to a maximum of 500 micrograms/kg per min or until the development of untoward side effects. The patients were then given oral nifedipine, 20 mg every hour, until a greater than or equal to 20% decrease in pulmonary vascular resistance or systemic hypotension occurred. The administration of maximal doses of adenosine, 256 +/- 46 micrograms/kg per min, produced a 2.4% reduction in pulmonary artery pressure (p = NS), a 37% decrease in pulmonary vascular resistance (p less than 0.001) and a 57% increase in cardiac index (p less than 0.001). The administration of maximally effective doses of nifedipine (91 +/- 36 mg) produced a 15% reduction in the mean pulmonary artery pressure (p less than 0.05), a 24% decrease in pulmonary vascular resistance (p less than 0.01) and an 8% increase in cardiac index (p = NS). There was a significant correlation (r = 0.714, p = 0.01) between the reduction in pulmonary vascular resistance that resulted from adenosine administration and that achieved with the administration of nifedipine. Six patients had substantial reductions in pulmonary vascular resistance with adenosine but not with nifedipine. Thus, adenosine is an effective vasodilator in patients with pulmonary hypertension and can be used for safe and rapid assessment of vasodilator reserve in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552096     DOI: 10.1016/0735-1097(92)90295-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Timed response to inhaled nitric oxide in pulmonary hypertension.

Authors:  James M Hunt; Michael G Risbano; John C Messenger; John Carroll; David Badesch; Brian D Lowes; Ivan P Casserly; Joseph Kay; Todd M Bull
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

2.  Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension.

Authors:  Wen-Hui Wu; Lu Yang; Fu-Hua Peng; Jing Yao; Li-Ling Zou; Dong Liu; Xin Jiang; Jue Li; Lan Gao; Jie-Ming Qu; Steven M Kawut; Zhi-Cheng Jing
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

3.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

Review 4.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  Overview of current therapeutic approaches for pulmonary hypertension.

Authors:  Jason A Stamm; Michael G Risbano; Michael A Mathier
Journal:  Pulm Circ       Date:  2011 Apr-Jun       Impact factor: 3.017

6.  Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension.

Authors:  Yan Wu; Fu-Hua Peng; Xin Gao; Xin-Xin Yan; FengWen Zhang; Jiang-Shan Tan; Song Hu; Lu Hua
Journal:  Front Cardiovasc Med       Date:  2022-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.